Retatrutide + Cagrilintide Blend
Triple incretin agonist combined with a long-acting amylin analog for combined metabolic pathway research. For laboratory and research use only.
Specifications
| Size | 15mg (Reta 12.5mg + Cagrilintide 2.5mg), 30mg (Reta 25mg + Cagrilintide 5mg) |
Description
Research Overview
This blend pairs Retatrutide, an agonist at the GLP-1, GIP and glucagon receptors, with Cagrilintide, a long-acting analog of amylin. The two act on separate systems — the incretin axis and the amylin receptor complex — and research interest in combining them rests on that separation rather than on any shared receptor. Amylin analogs have been investigated alongside incretin agonists in metabolic literature as a way of studying two satiety-related pathways in parallel.
Specifications
- Form: Lyophilized powder
- Storage: Store the powder refrigerated (2–8°C) or frozen, protected from light and moisture, until the printed expiry. After reconstitution, keep refrigerated (do not freeze); full potency ~1 month, with a noticeable quality drop after ~6 weeks.
For laboratory and research use only. Not for human consumption. This product is not a drug, food, or cosmetic and should not be used as a substitute for medical advice or treatment.
All products are sold strictly for in-vitro research and laboratory use only. Not for human consumption. By purchasing, you agree to our research policy and confirm you are a qualified researcher.